The significance of plasma collagen degradation products as biomarkers for advanced hypertensive heart disease
- PMID: 33932079
- PMCID: PMC8357153
- DOI: 10.1111/jch.14205
The significance of plasma collagen degradation products as biomarkers for advanced hypertensive heart disease
Conflict of interest statement
None.
Figures
Comment on
-
Angiotensin-converting enzyme inhibitors increase anti-fibrotic biomarkers in African Americans with left ventricular hypertrophy.J Clin Hypertens (Greenwich). 2021 May;23(5):1008-1016. doi: 10.1111/jch.14206. Epub 2021 Mar 10. J Clin Hypertens (Greenwich). 2021. PMID: 33694311 Free PMC article. Clinical Trial.
References
-
- Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem. 1995;64:403‐34. - PubMed
-
- Lang C, Sauter M, Szalay G, et al. Connective tissue growth factor: a crucial cytokine‐mediating cardiac fibrosis in ongoing enterovirus myocarditis. J Mol Med (Berl). 2008;86(1):49‐60. - PubMed
-
- Lopez B, Gonzalez A, Ravassa S, et al. Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. J Am Coll Cardiol. 2015;65(22):2449‐56. - PubMed
-
- Querejeta R, Lopez B, Gonzalez A, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004;110(10):1263‐8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
